Tonix Pharmaceuticals Holding (TNXP) Gross Margin (2023 - 2026)

Tonix Pharmaceuticals Holding's Gross Margin history runs 4 years deep, the most recent figure standing at 77.06% for Q1 2026.

• On a quarterly basis, Gross Margin rose 1588.0% year-over-year to 77.06% in Q1 2026; TTM through Mar 2026 was 58.56%, a 2875.0% increase from a year earlier, with the FY2025 full-year figure at 49.34%, up 2627.0% from the prior year.
• Gross Margin eased to 77.06% in Q1 2026 per TNXP's latest filing, from 80.37% in the prior quarter.
• Across five years, Gross Margin topped out at 80.37% in Q4 2025 and bottomed at 63.76% in Q2 2025.
• The 4-year median for Gross Margin is 44.9% (2024), against an average of 33.71%.
• Biggest YoY gain for Gross Margin was 2806 bps in 2025; the steepest drop was 1127 bps in 2025.
• Year by year, Gross Margin stood at 37.36% in 2023, then soared by 45 bps to 54.18% in 2024, then jumped by 48 bps to 80.37% in 2025, then fell by 4 bps to 77.06% in 2026.
• Per Business Quant, the three latest TNXP Gross Margin figures stand at 77.06% (Q1 2026), 80.37% (Q4 2025), and 58.45% (Q3 2025).